QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Signal Management for Biological Medicinal Products

Test your understanding of the concepts covered by Signal Management for Biological Medicinal Products.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which finding would provide the strongest support for a clinically meaningful antidrug-antibody concern?

A single positive antibody result obtained with an assay of unknown drug tolerance Antibody positivity accompanied by persistent or neutralising activity and compatible changes in pharmacokinetics, efficacy or hypersensitivity Antibody positivity measured only after treatment without any baseline information A change in antibody assay methodology with no clinical outcomes

Question 2 of 10 What is the most appropriate interpretation of a high disproportionality measure for a drug–event pair?

The event has a high incidence among exposed patients The medicine caused the event in the reported cases The event is reported more often than expected relative to other drug–event pairs in that database The event is more common with the medicine than in the general population

Question 3 of 10 Why should a biological-medicine signal system preserve brand and batch information wherever available?

Because all adverse events are caused by manufacturing defects Because product identity can distinguish active-substance effects from product-, batch-, formulation- or device-specific hypotheses Because brand and batch data eliminate the need for exposure denominators Because batch information is required only for quality complaints, not pharmacovigilance

Question 4 of 10 A manufacturing change altered glycan distribution within the approved comparability range, but the timing does not align with reported anaphylaxis. What is the most appropriate conclusion?

The manufacturing change is proven to be the cause because glycosylation changed The change is irrelevant because it remained within comparability limits The change-related explanation is weakened, although the clinical signal itself may still require assessment All products manufactured after the change must be recalled immediately

Question 5 of 10 Why must signal status and conclusions be reconciled across the tracker, PSUR, RMP and product information?

Because each document must contain identical wording regardless of purpose Because inconsistent status or conclusions can create contradictory regulatory and risk-management records Because the PSUR replaces the need for a signal tracker Because RMPs should include every individual case report

Question 6 of 10 Which statement best explains why a case-series definition is needed for delayed anaphylaxis after a biological medicine?

It ensures that every report with an anaphylaxis-related term is automatically included It permits consistent inclusion and exclusion and helps distinguish delayed immune reactions from infusion reactions, disease symptoms or excipient allergy It removes the need to review time to onset It converts the case series into an incidence study

Question 7 of 10 When does a product-quality deviation become pharmacovigilance-relevant?

Automatically, as soon as it is recorded in the quality system Only when it causes a statistically significant increase in adverse-event reports When patient exposure and a plausible clinical consequence exist, or when the defect itself requires safety action Only after a product recall has been completed

Question 8 of 10 A registry suggests more serious fungal infections among users of an immunomodulatory antibody. Which comparator would generally provide the most meaningful observed-versus-expected analysis?

The rate of fungal infection in the entire general population A population with comparable disease severity and concomitant immunosuppressive treatment The rate of all infections reported for unrelated medicines The number of fungal infections in the antibody's clinical trials only

Question 9 of 10 Which governance arrangement is most consistent with an inspection-ready biological signal-management system?

Unwritten responsibilities with decisions made by whichever function first reviews a case Defined methods, review frequency, ownership, escalation routes, competence, QPPV access and traceable decision records A single statistical threshold applied to every product regardless of exposure or risk Separate pharmacovigilance and quality systems with no formal information exchange

Question 10 of 10 What is the most appropriate purpose of effectiveness evaluation after a signal-management action?

To demonstrate that the original signal was never valid To determine whether the action achieved its intended effect, such as improved reporting quality or fewer device complaints To replace routine surveillance once the action is implemented To close the signal automatically on the date of implementation

Knowledge Assessment: Signal Management for Biological Medicinal Products

Cookie Settings